| 何彩云,谢东德,潘海强,洪旭灿,邹林,曾麒霖,孙培原,李威威.血清CYFRA21-1、SCCA、Pro-GRP、CEA、PCT、IL-6联合检测对肺癌诊断的临床价值分析.[J].中南医学科学杂志.,2024,(6):950-953. |
| 血清CYFRA21-1、SCCA、Pro-GRP、CEA、PCT、IL-6联合检测对肺癌诊断的临床价值分析 |
| Clinical value of combined detection of serum CYFRA21-1, SCCA, Pro-GRP, CEA, PCT and IL-6 in lung cancer diagnosis |
| 投稿时间：2024-05-29 修订日期：2024-08-27 |
| DOI：10.15972/j.cnki.43-1509/r.2024.06.018 |
| 中文关键词: 肺癌 PCT IL-6 CYFRA21-1 SCCA Pro-GRP CEA 联合检测 |
| 英文关键词:lung cancer PCT IL-6 CYFRA21-1 SCCA Pro-GRP CEA combined detection |
| 基金项目:广东省医学科研基金项目(A2024592)；佛山市科技创新项目(2220001003779) 作者简介:何彩云,副主任技师,研究方向为免疫学检验与临床,E-mail为1609459833@qq.com。通信作者李威威,硕士,检验师,研究方向为免疫学,E-mail为weiweili166@163.com。 |
| 作者 | 单位 | E-mail | | 何彩云 | 佛山市第二人民医院检验科,广东佛山528000 | e-mail为1609459833@qq.com,e-mail为weiweili166@163.com | | 谢东德 | 佛山市第二人民医院检验科,广东佛山528000 | | | 潘海强 | 佛山市第二人民医院检验科,广东佛山528000 | | | 洪旭灿 | 佛山市第二人民医院检验科,广东佛山528000 | | | 邹林 | 佛山市第二人民医院检验科,广东佛山528000 | | | 曾麒霖 | 南华大学衡阳医学院,湖南衡阳421001 | | | 孙培原 | 南华大学衡阳医学院,湖南衡阳421001 | | | 李威威 | 佛山市第二人民医院检验科,广东佛山528000 | e-mail为1609459833@qq.com,e-mail为weiweili166@163.com |
|
| 摘要点击次数: 68 |
| 全文下载次数: 31 |
| 中文摘要: |
| 目的分析细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCCA)、胃泌素释放肽前体(Pro-GRP)、癌胚抗原(CEA)、降钙素原(PCT)和白细胞介素(IL)-6联合检测对肺癌诊断的临床价值。 方法选取本院90例肺癌患者为肺癌组,90例肺部良性疾病患者为对照组和90例健康体检者为健康组。比较各组血清CYFRA21-1、Pro-GRP、SCCA、CEA、CRP、PCT和IL-6水平。采用多因素Logistic回归分析肺癌发生的影响因素。ROC曲线分析CYFRA21-1、SCCA、Pro-GRP、CEA、PCT和IL-6单独检测和联合检测对肺癌的诊断效能。 结果肺癌组CYFRA21-1、Pro-GRP、SCCA、CEA、CRP、PCT和IL-6水平高于健康组或对照组(P＜0.05)。肺癌组不同病理分型(肺腺癌、肺鳞癌和小细胞肺癌)CYFRA21-1、SCCA、Pro-GRP、CEA、PCT和IL-6水平差异无显著性(P＞0.05)。CYFRA21-1、Pro-GRP、SCCA、CEA、PCT、IL-6是肺癌发生的影响因素。CYFRA21-1、SCCA、Pro-GRP、CEA、PCT和IL-6联合检测的阳性率和AUC均优于单一指标检测。 结论血清CYFRA21-1、SCCA、Pro-GRP、CEA、PCT和IL-6联合检测对肺癌具有较高的诊断价值。 |
| 英文摘要: |
| AimTo evaluate the clinical value of combined detection of cyto-keratin 19 fragment antigen 21-1 (CYFRA21-1), squamous cell carcinoma antigen (SCCA), pro-gastrin-releasing peptide (Pro-GRP), carcinoembryonic antigen (CEA), procalcitonin (PCT), and interleukin-6 (IL-6) in the diagnosis of lung cancer. MethodsThis study included 90 lung cancer patients (lung cancer group), 90 patients with benign lung diseases (control group), and 90 healthy individuals (healthy group). Serum levels of CYFRA21-1, Pro-GRP, SCCA, CEA, CRP, PCT and IL-6 among the two groups were compared. Multivariate Logistic regression was employed to analyze the risk factors for lung cancer. ROC curve analysis were used to evaluate the diagnostic performance of individual and combined detection of serum CYFRA21-1, SCCA, Pro-GRP, CEA, PCT and IL-6. ResultsThe levels of CYFRA21-1, Pro-GRP, SCCA, CEA, CRP, PCT, and IL-6 were significantly higher in the lung cancer group than those in the healthy and control groups (P＜0.05). No significant differences were observed in the levels of CYFRA21-1, SCCA, Pro-GRP, CEA, PCT, and IL-6 across different pathological subtypes of lung cancer, including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (P＞0.05). CYFRA21-1, Pro-GRP, SCCA, CEA, PCT, and IL-6 were identified as risk factors for lung cancer. The combined detection of serum CYFRA21-1, SCCA, Pro-GRP, CEA, PCT and IL-6 showed superior positive detection rates and AUC compared with single-marker assays. ConclusionThe combined detection of serum CYFRA21-1, SCCA, Pro-GRP, CEA, PCT, and IL-6 demonstrates high diagnostic value for lung cancer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|